MARKET

CPRX

CPRX

Catalyst Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.33
+0.31
+4.42%
After Hours: 7.07 -0.26 -3.55% 19:01 05/27 EDT
OPEN
7.07
PREV CLOSE
7.02
HIGH
7.38
LOW
6.94
VOLUME
965.62K
TURNOVER
0
52 WEEK HIGH
8.65
52 WEEK LOW
4.810
MARKET CAP
753.38M
P/E (TTM)
17.62
1D
5D
1M
3M
1Y
5Y
Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences
CORAL GABLES, Fla., May 17, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with ...
GlobeNewswire · 05/17 12:03
Most likely large-cap and small-cap merger candidates -BofA
BofA Securities screened for stocks with the the characteristics most likely to attract suitors, both in the large- and small-cap universes. For S&P 500 (SP500) (SPY) targets, BofA: Screens based
Seekingalpha · 05/15 15:42
Catalyst Pharmaceuticals Q1 earnings rise Y/Y; reaffirms FY22 revenue outlook
Catalyst Pharmaceuticals (NASDAQ:CPRX) Q1 non-GAAP EPS grew +63.64% Y/Y to $0.18 and the company reaffirmed its FY22 revenue outlook. Total revenues rose +42.66% to $43.03M Y/Y. The company said the increase
Seekingalpha · 05/11 16:49
Catalyst Pharmaceuticals (NASDAQ:CPRX) pulls back 10% this week, but still delivers shareholders solid 27% CAGR over 5 years
Catalyst Pharmaceuticals, Inc. ( NASDAQ:CPRX ) shareholders might be concerned after seeing the share price drop 14% in...
Simply Wall St. · 05/11 10:05
Catalyst Pharmaceutical (CPRX) Misses Q1 Earnings and Revenue Estimates
Catalyst (CPRX) delivered earnings and revenue surprises of -14.29% and 0.19%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/10 21:25
Catalyst Pharmaceuticals Q1 EPS $0.18 Beats $0.14 Estimate, Sales $43.10M Beat $42.75M Estimate
Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.14 by 28.57 percent. This is a 157.14 percent increase over earnings of $0.07 per
Benzinga · 05/10 20:55
Catalyst Pharmaceuticals Non-GAAP EPS of $0.18, revenue of $43.09M
Catalyst Pharmaceuticals press release (NASDAQ:CPRX): Q1 Non-GAAP EPS of $0.18. Revenue of $43.09M (+42.6% Y/Y). Shares +1.6%. Guidance: The Company continues to forecast full year 2022 total revenues to be
Seekingalpha · 05/10 20:15
BRIEF-Catalyst Pharmaceuticals Reports First Quarter 2022 Results
reuters.com · 05/10 20:15
More
No Data
Learn about the latest financial forecast of CPRX. Analyze the recent business situations of Catalyst Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CPRX stock price target is 11.60 with a high estimate of 15.00 and a low estimate of 9.00.
High15.00
Average11.60
Low9.00
Current 7.33
EPS
Actual
Estimate
0.040.090.130.17
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 242
Institutional Holdings: 93.42M
% Owned: 90.89%
Shares Outstanding: 102.78M
TypeInstitutionsShares
Increased
56
8.07M
New
34
2.57M
Decreased
71
4.83M
Sold Out
14
980.88K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.69%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Chairman/Chief Executive Officer/President/Director
Patrick McEnany
Chief Financial Officer/Vice President/Treasurer
Alicia Grande
Chief Operating Officer/Chief Scientific Officer
Steven Miller
Chief Compliance Officer
Brian Elsbernd
Vice President
Mary Coleman
Other
Jeffrey Del Carmen
Other
Gary Ingenito
Lead Director/Independent Director
Charles O'Keeffe
Director
Molly Harper
Independent Director
Philip Coelho
Independent Director
Richard Daly
Independent Director
Donald Denkhaus
Independent Director
David Tierney
No Data
No Data
About CPRX
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company. The Company is focused on in-licensing, developing, and commercializing medicines for patients living with rare diseases. The Company is developing a pipeline of medicines for other rare diseases. The Company's product Firdapse Tablet, 10 mg, is used for the treatment of adults with Lambert-Eaton Myasthenic Syndrome (LEMS) patients (ages 17 and above) in the United States and Canada. Firdapse consists of the phosphate salt of amifampridine. It is developing a long-acting formulation of amifampridine phosphate. The Company's Firdapse is also developing clinical trials for the treatment of muscle-specific receptor tyrosine kinase-positive myasthenia gravis (MuSK-MG). Catalyst Pharmaceuticals Ireland, Ltd. is the subsidiary of the Company.

Webull offers kinds of Catalyst Pharmaceuticals Inc stock information, including NASDAQ:CPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CPRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CPRX stock methods without spending real money on the virtual paper trading platform.